What a New Drug Pricing Model could mean for Patients and Taxpayers
Drug costs can be inflated with pricing strategies from Pharmacy Benefit Managers (PBMs) who create additional hidden fees and use unethical pricing models that allow them to overcharge the health plans hundreds of millions of dollars each year.
How do they do this? PBMs are middlemen in the pharmaceutical pricing game. One of their roles is to negotiate “better pricing” for medications for health plans by communicating with the companies who make the medications. For this service, healthcare plans pay PBMs an administrative fee to find the best price, but most plans don’t realize that there are also hidden fees PBMs charge called spread pricing.
PBMs Spread Pricing Model is Inflating Drug Prices
Spread pricing is the difference between a reimbursement for a prescription, paid by insurance companies, and payments for prescription medications, the money paid to pharmacies.
That difference is referred to as spread pricing, and that money goes straight into the PBMs pockets.
Recent reports have shown that PBMs in Ohio and Kentucky were overcharging state governments by hundreds of millions of dollars.
- A 2018 audit in Ohio found that PBMs cost the state’s Medicaid Managed Care Plans almost $225 million with spread pricing fees over 30%1
- A 2019 Kentucky report revealed that PBMs charged $123.5 million to Medicaid plans with spread pricing2
With PBMs playing the middlemen, they have the ability to overcharge health plans and inflate the price you pay for your prescriptions without anyone knowing. In the end, it’s the employers and taxpayers paying for these plans who are paying the price. Imagine what you could do with an extra $100 million in tax money for your community!
What is a Pass-Through Pricing Model?
Pass-through pricing is a model where PBMs pass on the same fees and discounts from the pharmacy to the plan sponsor.
Pass-through pricing is much simpler than the current and complicated spread pricing model used by most PBMs.
With pass-through pricing there is just a simple administrative fee charged by the PBM for negotiating better prices for medications. This restricts PBMs from adding on extra fees and completely cuts out the spread pricing which is a significant source of inflated prices in today’s healthcare system.
Possible Solution for Controlling Inflated Drug Costs?
Some states have already adopted laws that restrict PBM spread pricing strategies, and many others have plans to introduce this.
Switching away from spread pricing to pass-through pricing will completely remove extra fees tacked on by PBMs. This will reduce the overall cost of prescription medications for employers, taxpayers, and patients.
Pass through pricing models also bring us closer to the original intention of PBMs, which was to help insurance companies and patients achieve better health outcomes by improving the appropriateness and affordability of medications.
Adoption of the pass-through model in the U.S. would be a major step forward in improving price transparency in the pharmaceutical industry.
How Drug Pricing Laws are Already Being Used
State laws restricting PBM pricing strategies have been adopted by states such as Georgia, Michigan, Mississippi, Ohio and Tennessee. Here’s some examples:
- Georgia introduced laws in 2020 requiring PBMs to offer plans that don’t include spread pricing. The laws now require PBMs to report when paying 10 percent above or below the average acquisition cost.3
- In light of the 31% spread pricing fees ($208 million) Ohio’s Auditor of State uncovered in 2018, Ohio introduced laws that will require PBMs to use pass-through pricing and have flat administrative fees.4 This change is expected to save Ohio taxpayers $150 to $200 million per year.
- Mississippi has prohibited spread pricing contracts with PBMs.5 They also filed a lawsuit against PBMs for overcharging state Medicaid programs and raising the prices of drugs like insulin despite lower production costs.6
Unfortunately, the majority of U.S. States haven’t created rules and regulations on spread pricing and most government and employer health plans are overpaying for medications.
Pass Through Pricing Laws can Save us Millions in Taxpayer Dollars
What you can do to Lower Drug Costs in your Own State
You’ve got the opportunity to tell your state government how they can save millions of taxpayer dollars each year. If you want more laws that restrict drug price inflation, contact your local Governor’s office. To find your Governor’s website click here.
Introducing new state laws to regulate drug pricing games is a real step forward in reducing the cost of prescription medications and improving pricing transparency in the pharmaceutical industry. Plus, it will save us hundreds of millions in healthcare costs each year.
You can also support businesses like Marley Drug who are challenging the system with new pharmacy models that by-pass insurance.
Marley Drug Completely Cuts out the PBMs
Generic medications are generally very inexpensive and account for 90% of all prescriptions in the U.S. In reality, there is no real reason why we need to pay a PBM to negotiate a better price for our generic medications, because they are already so inexpensive. So instead, at Marley Drug we offer our generic medications for a cash-price. This means there’s no insurance company involved. Many of our customers are surprised to learn that paying cash can save them money.
Advantages of not having to pay via insurance:
- PBMs can’t get involved.
- No insurance headaches or pre-approval required
- No administrative fees, and no spread pricing fees added on to your medication prices.
At Marley Drug we offer a flat, transparent price. Through our Extended Drug Supply Program we offer over 100 generic medications at just $37 for a 6-month supply, or $70 for a 12-month supply. This includes free shipping. That is only ~$6 a month!
Call 800-810-7790 to ask about how you can save on your prescriptions.
- Ohio's Medicaid Managed Care Pharmacy Services Auditor of State Report. Published on August 16, 2018 Medicaid Pharmacy Pricing. Opening the Black Box. Kentucky Cabinet for Health and Family Services. Published February 19, 2019
- Georgia enacts trio of PBM reform bills. National Community Pharmacists Association (NCPA). Published August 7, 2020
- Auditor’s Report: Pharmacy Benefit Managers Take Fees of 31% on Generic Drugs Worth $208M in One-Year Period. Ohio Auditor of State. Published. August 16, 2018
- Mississippi Legislature. Senate Bill 2323. 2021 Regular Session
- Mississippi first state to sue drugmakers, PBMs over 'egregiously inflated' insulin costs. Becker's Hospital Review. Published June 15, 2021